FDA Issues Safety Warnings on Boston Scientific Heart Devices Linked to Injuries and Fatalities
The FDA has issued safety warnings on Boston Scientific heart devices, alerting healthcare providers and patients about risks of device failure, injuries, and deaths associated with defibrillator wires and the Watchman stroke prevention device.
The U.S. Food and Drug Administration (FDA) has issued safety alerts concerning two Boston Scientific heart devices that have been associated with serious injuries and fatalities. The agency specifically highlighted issues with the company's Endotak Reliance defibrillator wires and the Watchman device used for stroke prevention.
For the defibrillators, the FDA reports that the wires can develop calcification over time, which may lead to device failure in delivering life-saving shocks during cardiac emergencies. This problem has resulted in 386 serious injuries and 16 deaths as reported by Boston Scientific up to July 24. Among the fatalities, ten were attributed to device malfunction, while others involved surgical removal procedures or were deemed unrelated.
These wires were distributed between 2002 and 2021 and are no longer available. Patients with these devices might require replacement, though medical professionals should consider the risks associated with surgical removal.
Separately, the FDA also addressed concerns related to Boston Scientific's Watchman device, which is implanted in the heart's left atrium to reduce stroke risk in patients with atrial fibrillation. The company recently updated its implantation instructions after discovering an increased risk of bloodstream blockages during the procedure, especially depending on anesthesia levels. As of July 30, there have been 120 serious injuries and 17 deaths linked to issues with the Watchman device. A company investigation found that these safety concerns are not related to the design or manufacturing defects.
Boston Scientific's heart-related products are a significant part of its revenue, comprising about two-thirds of its $5 billion quarterly income. The company has alerted healthcare providers to these issues and emphasized careful patient selection and procedural considerations.
Shares of Boston Scientific saw a decrease of approximately 1.8%, closing at $102.95 following the news. Patients and clinicians are advised to stay informed about these safety concerns and consult healthcare professionals for appropriate management.
source: https://medicalxpress.com/news/2025-08-fda-flags-problems-boston-scientific.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
New Brain Cell Discovery Could Unlock Secrets to Alzheimer's-Related Disorientation
Researchers have identified a unique neuron in the retrosplenial cortex that encodes the sense of direction, offering new insights into Alzheimer’s-related disorientation and potential avenues for treatment.
Q&A: Debunking 8 Common Myths About Back Pain
Learn the facts behind common misconceptions about back pain, including causes, treatments, and prevention tips to help you manage and protect your spinal health.
FDA Approves Opzelura Cream for Atopic Dermatitis in Young Children
The FDA has approved Opzelura, a JAK inhibitor cream, for children aged 2-11 with atopic dermatitis, providing an effective new treatment option for young patients.
Advancements in Deep Learning for Lung Cancer Risk Prediction Using Single LDCT Scans
New deep learning model predicts lung cancer risk from a single LDCT scan, aiding personalized screening strategies and early detection efforts.